KALV logo

KALV
KalVista Pharmaceuticals Inc

3,080
Mkt Cap
$1.43B
Volume
1.57M
52W High
$26.85
52W Low
$9.83
PE Ratio
-6.70
KALV Fundamentals
Price
$26.79
Prev Close
$26.77
Open
$26.78
50D MA
$21.67
Beta
0.84
Avg. Volume
5.02M
EPS (Annual)
-$3.23
P/B
-69.85
Rev/Employee
$267,698.18
$806.04
Loading...
Loading...
News
all
press releases
Are KALV, GBTG, MDV, CPRX Obtaining Fair Deals for their Shareholders?
Are KALV, GBTG, MDV, CPRX Obtaining Fair Deals for their Shareholders? Are KALV, GBTG, MDV, CPRX Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 19, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed...
News Placeholder
More News
News Placeholder
KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of KalVista Pharmaceuticals, Inc. (NasdaqGM: KALV...
News Placeholder
Are SILA, KALV, THR, LSTA Obtaining Fair Deals for their Shareholders?
Are SILA, KALV, THR, LSTA Obtaining Fair Deals for their Shareholders? Are SILA, KALV, THR, LSTA Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 14, 2026 Insiders may stand to...
News Placeholder
Are RMAX, KALV, GBTG Obtaining Fair Deals for their Shareholders?
Are RMAX, KALV, GBTG Obtaining Fair Deals for their Shareholders? Are RMAX, KALV, GBTG Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 8, 2026 Insiders may stand to receive...
News Placeholder
KalVista Pharmaceuticals (NASDAQ:KALV) Reaches New 1-Year High - Here's Why
KalVista Pharmaceuticals (NASDAQ:KALV) Hits New 1-Year High - Still a Buy...
News Placeholder
Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders?
Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders? Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 4, 2026 Insiders may stand to receive...
News Placeholder
KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of KalVista Pharmaceuticals, Inc. (NasdaqGM: KALV...
News Placeholder
KalVista Pharmaceuticals (NASDAQ:KALV) Rating Lowered to "Neutral" at HC Wainwright
HC Wainwright cut shares of KalVista Pharmaceuticals from a "buy" rating to a "neutral" rating and set a $27.00 price target on the stock. in a research report on Friday...
News Placeholder
KalVista Pharmaceuticals (NASDAQ:KALV) Stock Rating Lowered by JonesTrading
JonesTrading lowered KalVista Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Thursday...
News Placeholder
KalVista Pharmaceuticals (NASDAQ:KALV) Given "Hold" Rating at Needham & Company LLC
Needham & Company LLC reiterated a "hold" rating on shares of KalVista Pharmaceuticals in a report on Thursday...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available